AI in IBD: Redefining Clinical Trials and the Future of Gastroenterology

EMJ Podcast: Insights For Healthcare Professionals · Jan 8, 2026 · 1m

Byrne discusses Dova's recent Late Breaker at the United European Gastroenterology (UEG) Week 2025, where AI re-analysis uncovered treatment effects missed by human readers. He explains how AI may soon become integral to clinical trial design, regulatory review, and drug approval, while predicting how AI-human partnerships will define the future of gastroenterology. Timestamps:01:05 – AI in the TITRATE trial03:18 – Validating clinical endpoints04:16 – AI and human readers16:53 – The next frontier in gastrointestinal AI